In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs

Methods

Volumn 103, Issue , 2016, Pages 167-174

  Urak, Kevin T ^a   Shore, Sabrina ^b   Rockey, William M ^a   Chen, Shi Jie ^c   McCaffrey, Anton P ^b   Giangrande, Paloma H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b TriLink BioTechnologies Inc   (United States)

^c Department of Biochemistry and Informatics Institute ^*  (United States)

Author keywords

2' Fluoro pyrimidines; Illumina sequencing; In vitro SELEX; Modified nucleotides; Mutant T7 RNA polymerase; Next generation sequencing; Recombinant proteins; RNA aptamers

Indexed keywords

APTAMER;

ANALYTIC METHOD; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL PROCEDURES; CHEMICAL STRUCTURE; IN VITRO STUDY; MICROFLUIDICS; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS OPTIMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; DRUG DESIGN; HIGH THROUGHPUT SEQUENCING; HUMAN; ISOLATION AND PURIFICATION; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; DRUG DESIGN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELEX APTAMER TECHNIQUE; SEQUENCE ANALYSIS, RNA;

EID: 84960393271     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2016.03.003     Document Type: Article

References (44)

1. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nat. Rev. Drug. Discovery 2010, 9(7):537-550.
2. Diafa S., Hollenstein M. Generation of aptamers with an expanded chemical repertoire. Molecules 2015, 20(9):16643-16671.
3. Dassie J.P., et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol. Ther. 2014, 22(11):1910-1922.
4. Rockey W.M., et al. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011, 21(5):299-314.
5. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346(6287):818-822.
6. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510.
7. Tasset D.M., Kubik M.F., Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J. Mol. Biol. 1997, 272(5):688-698.
8. Bruno J.G., Kiel J.L. In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens. Bioelectron. 1999, 14(5):457-464.
9. Jenison R.D., et al. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev. 1998, 8(4):265-279.
10. Blank M., et al. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem. 2001, 276(19):16464-16468.
11. Rusconi C.P., et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419(6902):90-94.
12. Giangrande P.H., et al. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(32):12988-12993.
13. Mi J., et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther. 2008, 16(1):66-73.
14. Lee J.W., Kim H.J., Heo K. Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep. 2015, 48(4):234-237.
15. McNamara J.O., et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 2008, 118(1):376-386.
16. Sundaram P., et al. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 2013, 48(1-2):259-271.
17. Ruckman J., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998, 273(32):20556-20567.
18. Floege J., et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 1999, 154(1):169-179.
19. Adler A., et al. Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb. Chem. High Throughput Screening 2008, 11(1):16-23.
20. Sousa R., Padilla R. A mutant T7 RNA polymerase as a DNA polymerase. EMBO J. 1995, 14(18):4609-4621.
21. Siegmund V., et al. Screening mutant libraries of T7 RNA polymerase for candidates with increased acceptance of 2'-modified nucleotides. Chem. Commun. (Camb.) 2012, 48(79):9870-9872.
22. Chelliserrykattil J., Ellington A.D. Evolution of a T7 RNA polymerase variant that transcribes 2'-O-methyl RNA. Nat. Biotechnol. 2004, 22(9):1155-1160.
23. Padilla R., Sousa R. A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res. 2002, 30(24):e138.
24. Burmeister P.E., et al. 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 2006, 16(4):337-351.
25. Thiel K.W., et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012, 40(13):6319-6337.
26. Thiel W.H., et al. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One 2012, 7(9):e43836.
27. Huang Y.Z., et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol. Pharmacol. 2012, 82(4):623-635.
28. Thiel W.H., et al. Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther. 2011, 21(4):253-263.
29. Cho M., et al. Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(35):15373-15378.
30. Hoinka J., et al. Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucleic Acids Res. 2015, 43(12):5699-5707.
31. Swensen J.S., et al. Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic, electrochemical aptamer-based sensor. J. Am. Chem. Soc. 2009, 131(12):4262-4266.
32. Jenison R.D., et al. High-resolution molecular discrimination by RNA. Science 1994, 263(5152):1425-1429.
33. McKeague M., DeRosa M.C. Challenges and opportunities for small molecule aptamer development. J. Nucleic Acids 2012, 2012.
34. Lorger M., et al. Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryot. Cell 2003, 2(1):84-94.
35. Cheng C., et al. In vivo SELEX for identification of brain-penetrating aptamers. Mol. Ther. Nucleic Acids 2013, 2:e67.
36. Mi J., et al. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 2010, 6(1):22-24.
37. Stoltenburg R., Reinemann C., Strehlitz B. SELEX - a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24(4):381-403.
38. Szeto K., et al. High-throughput binding characterization of RNA aptamer selections using a microplate-based multiplex microcolumn device. Anal. Bioanal. Chem. 2014, 406(11):2727-2732.
39. Blind M., Blank M. Aptamer selection technology and recent advances. Mol. Ther. Nucleic Acids 2015, 4(1):e223.
40. Ohuchi S. Cell-SELEX technology. BioRes. Open Access 2012, 1(6):265-272.
41. Thiel W.H., Giangrande P.H. Analyzing HT-SELEX data with the galaxy project tools - a web based bioinformatics platform for biomedical research. Methods 2015.
42. Zhou J., Rossi J.J. Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol. Biol. 2011, 721:355-371.
43. Liu L., et al. Comparison of next-generation sequencing systems. BioMed Res. Int. 2012, 2012.
44. Metzker M.L. Sequencing technologies-the next generation. Nat. Rev. Genet. 2010, 11(1):31-46.